DPD variants
Pharmacogenetic Biomarker
DPD variants
Selected Variants (Mutant Allele, Enzyme Activity)
DPYD*2A (1905+1G>A, none);
DPYD*13 (1679T>G, ↓↓);
DPYD rs67376798 (2846A>T, ↓↓)
Allele Frequency
These non-functional variants are present in 0.1–1% of whites (eg, French Caucasians)
Drugs
5-fluorouracil (5-FU), capecitabine (Xeloda)
Clinical Relevance
Fluoropyrimidines (ie, 5-fluorouracil, capecitabine) are metabolized by dihydropyrimidine dehydrogenase (DPD) enzyme, encoded by the DPYD gene. To avoid severe or even fatal drug toxicity, an alternative drug should be selected for patients who are homozygous for DPYD non-functional variants (*2A, *13, or rs67376798). Consider a 50% reduction in starting dose for heterozygous patients who have low DPD activity (30–70% of normal).
To view other topics, please log in or purchase a subscription.
Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drugs, procedures, and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and PRIME Journals. Complete Product Information.